Structure-Activity Relationships of Anthranilamide-Based Factor Xa Inhibitors Containing Piperidinone and Pyridinone P4 Moieties
Corte, J.R., Fang, T., Pinto, D.J.P., Han, W., Hu, Z., Jiang, X.-J., Li, Y.-L., Gauuan, J.F., Hadden, M., Orton, D., Rendina, A.R., Luettgen, J.M., Wong, P.C., He, K., Morin, P., Chang, C.-H., Cheney, D.L., Knabb, R.M., Wexler, R.R., Lam, P.Y.S.(2008) Bioorg Med Chem Lett 18: 2845-2849
- PubMed: 18424044 
- DOI: https://doi.org/10.1016/j.bmcl.2008.03.092
- Primary Citation of Related Structures:  
3CEN - PubMed Abstract: 
Introduction of the phenyl piperidinone and phenyl pyridinone P4 moieties in the anthranilamide scaffold led to potent, selective, and orally bioavailable inhibitors of factor Xa. Anthranilamide 28 displayed comparable efficacy to apixaban in the rabbit arteriovenous-shunt (AV) thrombosis model.
Organizational Affiliation: 
Bristol-Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08543, USA. james.corte@bms.com